Dr. Radovich captures the energy in the hallways this year: the convergence of agentic AI with massive genomic datasets is inspiring a new era of care: better prediction algorithms, more powerful diagnostic tools, and research happening at a scale we've never seen before.
He highlights a targeted agent going after genomic targets with significant response rates, including a pill that is increasing survival in pancreatic cancer - one of oncology's most stubborn challenges. Caris Life Sciences, together with the Precision Oncology Alliance, presented 32 posters at ASCO this year, including groundbreaking research in collaboration with the National Cancer Center of Japan demonstrating the real-world benefits of whole genome sequencing and a significant increase in identifying actionable cancer targets.
But what truly brings it home? Early detection. Dr. Radovich makes the case that catching cancer earlier is the number one predictor of bending the survival curve and with the tools now at our disposal, that future feels closer than ever.
Be sure to like and subscribe to HITea with Grace for honest conversations at the intersection of health, innovation, and technology!